Emcure margin expands as costs lag revenue; stock slips 1.97%
Standalone margin also rose 4.13 percentage points sequentially, but lower other income and a higher tax rate pulled net profit down 9.72% from Q3FY26.
Filed 05 May 2026, 20:59 IST · after market close · Emcure Pharmaceuticals Ltd (EMCURE)
Key takeaways
- Standalone operating margin rose 6.18 percentage points YoY to 25.32% as revenue grew 14.83% while expenses grew 6.05%.
- Net profit increased 67.45% YoY to Rs 233.7 cr, but other income contributed 11.27% of pre-tax profit and the tax rate was 23.69%.
- The stock fell 1.97% by the fifth session after results, a smaller move than its 3.19% median absolute post-results move across seven observations.
Price around the results
Margin rebound reaches 25.32%
Revenue grew 14.83% YoY, while expenses rose 6.05%, allowing operating profit to increase 51.92% and operating margin to widen 6.18 percentage points. Sequentially, revenue increased 3.48% as expenses fell 1.95%, lifting margin by 4.13 percentage points. The 25.32% standalone margin was 1.94 percentage points above the 23.38% median for 48 Healthcare peers that had reported.
Sequential profit was diluted by other income and tax
Operating profit rose 23.68% sequentially, but pre-tax profit fell 2.58% because other income dropped 68.37%, interest expense increased 11.22% and the tax rate rose 6.03 percentage points. Other income still accounted for 11.27% of pre-tax profit, so reported profit growth was not entirely operating-led. YoY, the tax rate fell 1.3 percentage points, which provided a modest additional lift to the 67.45% increase in net profit.
Margin has recovered for two straight quarters
Operating margin moved from 17.82% in Q2FY26 to 21.19% in Q3FY26 and 25.32% in Q4FY26. This marks a second consecutive quarterly expansion after the Q2FY26 trough, while the current margin is also 6.18 percentage points above Q4FY25.
International growth and portfolio additions feature in management update
Management said the international business delivered 22% YoY revenue growth and margin expansion in FY26. The company said it fully consolidated Zuventus through a minority stake buyout and acquired Manx in Europe and Cutimed in Canada. Management said Roche brands for CKD, anaemia management and transplant care are planned for distribution from Q1FY27, while Lenacapavir registration is expected in FY27.
Initial stock reaction was milder than its usual move
The stock fell 1.82% on the first session after the results and was down 1.97% by the fifth session, despite a 0.87% opening gap higher. That five-session decline was smaller than the 3.19% median absolute move across seven recent result reactions; the stock rose after three and fell after four of those results. It was up 2.07% by day 15 and 3.72% by day 30.
Q4FY26 at a glance
Standalone figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹1,468 cr | ₹1,418 cr | +3.48% | +14.83% |
| Other income | ₹35 cr | ₹109 cr | -68.37% | +54.11% |
| Expenses | ₹1,096 cr | ₹1,118 cr | -1.95% | +6.05% |
| Operating profit | ₹372 cr | ₹301 cr | +23.68% | +51.92% |
| Operating margin (%) | 25.32% | 21.19% | — | — |
| Interest | ₹37 cr | ₹33 cr | +11.22% | +53.18% |
| Depreciation | ₹63 cr | ₹62 cr | +1.45% | +10.77% |
| Profit before tax | ₹306 cr | ₹314 cr | -2.58% | +64.62% |
| Tax | ₹73 cr | ₹56 cr | +30.73% | +56.10% |
| Net profit | ₹234 cr | ₹259 cr | -9.72% | +67.45% |
| EPS (₹) | ₹12.33 | ₹13.65 | -9.67% | +67.30% |
Operating margin of 25.32% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -1.82% | -3.06% |
| Next session | -1.51% | — |
| 5 sessions | -1.97% | +0.61% |
| 15 sessions | +2.07% | — |
| 30 sessions | +3.72% | — |
Volume on the results session was 1.58× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- International business delivered 22% year-on-year revenue growth and margin expansion in FY26.
Guidance & outlook
- The company crossed US$1 billion in revenue and achieved 16.6% growth, above its guidance.
- Registration of the Lenacapavir product is expected in FY27.
Planned next quarter
- Roche brands for CKD, anaemia management and transplant care are planned for distribution from Q1FY27.
Expansion
- The company fully consolidated Zuventus through a minority stake buyout.
- The company acquired Manx in Europe and Cutimed in Canada.
- The company will distribute Roche brands for CKD, anaemia management and transplant care from Q1FY27.
What to watch
- Whether standalone operating margin holds above 25.32%.
- Whether other income remains close to 11.27% of pre-tax profit.
- Whether international revenue growth remains near the 22% FY26 level.